424 related articles for article (PubMed ID: 30340863)
21. Optimisation of vancomycin exposure in neonates based on the best level of evidence.
Dao K; Guidi M; André P; Giannoni E; Basterrechea S; Zhao W; Fuchs A; Pfister M; Buclin T; Csajka C
Pharmacol Res; 2020 Apr; 154():104278. PubMed ID: 31108184
[TBL] [Abstract][Full Text] [Related]
22. Achievement of Therapeutic Vancomycin Exposure With Continuous Infusion in Critically Ill Children.
Genuini M; Oualha M; Bouazza N; Moulin F; Treluyer JM; Lesage F; Renolleau S; Benaboud S
Pediatr Crit Care Med; 2018 Jun; 19(6):e263-e269. PubMed ID: 29394210
[TBL] [Abstract][Full Text] [Related]
23. Risk of Acute Kidney Injury Based on Vancomycin Target Trough Attainment Strategy: Area-Under-the-Curve-Guided Bayesian Software, Nomogram, or Trough-Guided Dosing.
Knight JM; Iso T; Perez KK; Swan JT; Janak CE; Ikwuagwu JO; Musick WL
Ann Pharmacother; 2024 Feb; 58(2):110-117. PubMed ID: 37144736
[TBL] [Abstract][Full Text] [Related]
24. Allometric versus consensus guideline dosing in achieving target vancomycin trough concentrations.
Brown ML; Hutchison AM; McAtee AM; Gaillard PR; Childress DT
Am J Health Syst Pharm; 2017 Jul; 74(14):1067-1075. PubMed ID: 28522643
[TBL] [Abstract][Full Text] [Related]
25. The importance of empiric antibiotic dosing in critically ill trauma patients: Are we under-dosing based on augmented renal clearance and inaccurate renal clearance estimates?
Barletta JF; Mangram AJ; Byrne M; Hollingworth AK; Sucher JF; Ali-Osman FR; Shirah GR; Dzandu JK
J Trauma Acute Care Surg; 2016 Dec; 81(6):1115-1121. PubMed ID: 27533906
[TBL] [Abstract][Full Text] [Related]
26. Improved vancomycin dosing in children using area under the curve exposure.
Le J; Bradley JS; Murray W; Romanowski GL; Tran TT; Nguyen N; Cho S; Natale S; Bui I; Tran TM; Capparelli EV
Pediatr Infect Dis J; 2013 Apr; 32(4):e155-63. PubMed ID: 23340565
[TBL] [Abstract][Full Text] [Related]
27. Continuous infusion vs intermittent vancomycin in neurosurgical intensive care unit patients.
Hong LT; Goolsby TA; Sherman DS; Mueller SW; Reynolds P; Cava L; Neumann R; Kiser TH
J Crit Care; 2015 Oct; 30(5):1153.e1-6. PubMed ID: 26239323
[TBL] [Abstract][Full Text] [Related]
28. Vancomycin dosing in children and young adults: back to the drawing board.
Camaione L; Elliott K; Mitchell-Van Steele A; Lomaestro B; Pai MP
Pharmacotherapy; 2013 Dec; 33(12):1278-87. PubMed ID: 24019205
[TBL] [Abstract][Full Text] [Related]
29. Vancomycin dosing and target attainment in children.
Hwang D; Chiu NC; Chang L; Peng CC; Huang DT; Huang FY; Chi H
J Microbiol Immunol Infect; 2017 Aug; 50(4):494-499. PubMed ID: 26462708
[TBL] [Abstract][Full Text] [Related]
30. Prospective evaluation of vancomycin pharmacokinetics in a heterogeneous critically ill population.
Turner RB; Kojiro K; Won R; Chang E; Chan D; Elbarbry F
Diagn Microbiol Infect Dis; 2018 Dec; 92(4):346-351. PubMed ID: 30025969
[TBL] [Abstract][Full Text] [Related]
31. Dosing vancomycin in the super obese: less is more.
Crass RL; Dunn R; Hong J; Krop LC; Pai MP
J Antimicrob Chemother; 2018 Nov; 73(11):3081-3086. PubMed ID: 30203073
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of a vancomycin dosing nomogram in achieving high target trough concentrations in Taiwanese patients.
Leu WJ; Liu YC; Wang HW; Chien HY; Liu HP; Lin YM
Int J Infect Dis; 2012 Nov; 16(11):e804-10. PubMed ID: 22917921
[TBL] [Abstract][Full Text] [Related]
33. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software.
Nunn MO; Corallo CE; Aubron C; Poole S; Dooley MJ; Cheng AC
Ann Pharmacother; 2011 Jun; 45(6):757-63. PubMed ID: 21652786
[TBL] [Abstract][Full Text] [Related]
34. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*.
Jamal JA; Udy AA; Lipman J; Roberts JA
Crit Care Med; 2014 Jul; 42(7):1640-50. PubMed ID: 24674926
[TBL] [Abstract][Full Text] [Related]
35. Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study.
Blot S; Koulenti D; Akova M; Bassetti M; De Waele JJ; Dimopoulos G; Kaukonen KM; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Lipman J; Roberts JA
Crit Care; 2014 May; 18(3):R99. PubMed ID: 24887569
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of vancomycin target trough attainment with published dosing regimens in the neonatal intensive care unit population.
Chung E; Lee SE; Abraham T; Saad NN; Gad A
J Neonatal Perinatal Med; 2019; 12(1):21-27. PubMed ID: 30149480
[TBL] [Abstract][Full Text] [Related]
37. Individualized Pharmacokinetic Dosing of Vancomycin Reduces Time to Therapeutic Trough Concentrations in Critically Ill Patients.
Truong J; Smith SR; Veillette JJ; Forland SC
J Clin Pharmacol; 2018 Sep; 58(9):1123-1130. PubMed ID: 29957824
[TBL] [Abstract][Full Text] [Related]
38. [Clinical study of vancomycin for appropriate dosing in severe infective patients with augmented renal clearance].
Liu N; Zhang B; Liu Y; Tang J; Dong D; Gu Q
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2018 Jul; 30(7):646-651. PubMed ID: 30045791
[TBL] [Abstract][Full Text] [Related]
39. Evaluation and Development of Vancomycin Dosing Schemes to Meet New AUC/MIC Targets in Intermittent Hemodialysis Using Monte Carlo Simulation Techniques.
Lewis SJ; Mueller BA
J Clin Pharmacol; 2021 Feb; 61(2):211-223. PubMed ID: 32851685
[TBL] [Abstract][Full Text] [Related]
40. Pediatric Assessment of Vancomycin Empiric Dosing (PAVED): a Retrospective Review.
Rainkie D; Ensom MH; Carr R
Paediatr Drugs; 2015 Jun; 17(3):245-53. PubMed ID: 25813682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
